{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=29", "query": { "condition": "Advanced Malignancy", "page": 29 }, "page_size": 10 }, "pagination": { "page": 29, "page_size": 10, "total_count": 9808, "total_pages": 981, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=30&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=28&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T17:43:46.103Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04330664", "title": "Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Metastatic Cancer", "Malignant Neoplastic Disease" ], "interventions": [ { "name": "MRTX849", "type": "DRUG" }, { "name": "TNO155", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirati Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 86, "start_date": "2020-04-07", "completion_date": "2025-02-24", "has_results": false, "last_update_posted_date": "2025-04-04", "last_synced_at": "2026-10-31T17:43:46.103Z", "location_count": 17, "location_summary": "Los Angeles, California • Orange, California • Chicago, Illinois + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04330664" }, { "nct_id": "NCT00165464", "title": "Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer", "GE Junction Cancer" ], "interventions": [ { "name": "Taxotere", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2001-08", "completion_date": "2009-04", "has_results": false, "last_update_posted_date": "2009-04-28", "last_synced_at": "2026-10-31T17:43:46.103Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00165464" }, { "nct_id": "NCT02134067", "title": "Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "TAS-119", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2014-08", "completion_date": "2018-07", "has_results": false, "last_update_posted_date": "2024-09-05", "last_synced_at": "2026-10-31T17:43:46.103Z", "location_count": 4, "location_summary": "Aurora, Colorado • St Louis, Missouri • New York, New York + 1 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02134067" }, { "nct_id": "NCT05047536", "title": "KZR-261 in Subjects With Advanced Solid Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced/Metastatic Solid Tumor" ], "interventions": [ { "name": "KZR-261", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kezar Life Sciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2021-09-30", "completion_date": "2025-01-17", "has_results": true, "last_update_posted_date": "2025-12-19", "last_synced_at": "2026-10-31T17:43:46.103Z", "location_count": 12, "location_summary": "Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05047536" }, { "nct_id": "NCT07680764", "title": "A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Non-Small Cell Lung Cancer (NSCLC)", "Metastatic Non-Small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "Pumitamig", "type": "DRUG" }, { "name": "Imzokitug", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2026-09-10", "completion_date": "2030-09-15", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-31T17:43:46.103Z", "location_count": 12, "location_summary": "Washington D.C., District of Columbia • Athens, Georgia • Lexington, Kentucky + 8 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Athens", "state": "Georgia" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07680764" }, { "nct_id": "NCT00489593", "title": "Olanzapine in Patients With Advanced Cancer and Weight Loss", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Weight Loss" ], "interventions": [ { "name": "Olanzapine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 57, "start_date": "2006-10", "completion_date": "2013-12", "has_results": false, "last_update_posted_date": "2015-01-08", "last_synced_at": "2026-10-31T17:43:46.103Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00489593" }, { "nct_id": "NCT04173507", "title": "Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lung Non-Squamous Non-Small Cell Carcinoma", "Recurrent Lung Non-Squamous Non-Small Cell Carcinoma", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Talazoparib", "type": "DRUG" }, { "name": "Talazoparib Tosylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 47, "start_date": "2020-02-14", "completion_date": "2024-05-01", "has_results": true, "last_update_posted_date": "2024-09-03", "last_synced_at": "2026-10-31T17:43:46.103Z", "location_count": 325, "location_summary": "Mobile, Alabama • Little Rock, Arkansas • Anaheim, California + 257 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Baldwin Park", "state": "California" }, { "city": "Bellflower", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04173507" }, { "nct_id": "NCT05584111", "title": "Oral Administration of STC-15 in Subjects With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Advanced Solid Tumor", "Cancer" ], "interventions": [ { "name": "STC-15", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "STORM Therapeutics LTD", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2022-11-15", "completion_date": "2024-12-22", "has_results": false, "last_update_posted_date": "2025-03-26", "last_synced_at": "2026-10-31T17:43:46.103Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Houston, Texas • San Antonio, Texas", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05584111" }, { "nct_id": "NCT07098299", "title": "Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2025-09-18", "completion_date": "2028-07-07", "has_results": false, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-10-31T17:43:46.103Z", "location_count": 10, "location_summary": "Bay City, Michigan • Clarkston, Michigan • Detroit, Michigan + 7 more", "locations": [ { "city": "Bay City", "state": "Michigan" }, { "city": "Clarkston", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Flint", "state": "Michigan" }, { "city": "Lansing", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT07098299" }, { "nct_id": "NCT06710132", "title": "Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors", "Gastric Cancer", "Non-Small Cell Lung Cancer (NSCLC)", "Pancreatic Cancer", "Pancreatic Ductal Adenocarcinoma (PDAC)" ], "interventions": [ { "name": "M9140", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 184, "start_date": "2025-01-29", "completion_date": "2027-12-23", "has_results": false, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-10-31T17:43:46.103Z", "location_count": 8, "location_summary": "Santa Monica, California • Santa Rosa, California • Washington D.C., District of Columbia + 5 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Margate", "state": "Florida" }, { "city": "Greenville", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06710132" } ] }